MedTrace Logo

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

NCT03958045 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.

Conditions

Interventions

COMBINATION_PRODUCT

Rucaparib and Nivolumab

Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)

Sponsors & Collaborators

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • Zhonglin Hao

    lead OTHER

Principal Investigators

  • Zhonglin Hao, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2022-11-15
Completion
2022-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03958045 on ClinicalTrials.gov